Polymeric Nanopaclitaxel Compared with Free Paclitaxel for Actions on MCF-7 and B16F0 Carcinoma Cells

Breast cancer is the second most common leading cause of death in women. Acquired resistance of breast cancer cells is a challenging field in the research. Cancer becomes due to environmental and hereditary factors like chemicals, viruses, or radiation can cause DNA damage that leads to genetic mutations (Tabar and Dean, 2003). From a long time, many strategies have been developed and followed for prevention, diagnosis, and treatment of breast cancer. Mastectomy is a surgical, and preferable option, for treatment that has been replaced by lumpectomy, a radiation therapy (Lerner, 2001). Now, chemotherapy has become the usual treatment for breast cancer patients which helps reduce metastatic tumors (Gurses and Topcul, 2013). Paclitaxel is chemotherapeutic agent made from Yew trees and mitotic inhibitor that used widely in the treatment of breast cancer. Paclitaxel prevents cancer cells